As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...

Pennsylvanians deserve better than counterfeit medicine cooked up in back rooms and peddled through predatory online ads.

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

Those weight loss drugs that have been so out of reach for many, may soon be affordable, even if you don't have insurance.

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

A small new study suggests that people who’ve used GLP-1 drugs to reach a healthy weight can spread out their injections without regaining lost pounds.